Baseline characteristics
| Characteristic . | Patients (n = 25) . |
|---|---|
| Age, median (range), y | 13.5 (1-22.5) |
| Risk category, n (%) | |
| Relapse following allo-HSCT | 5 (20) |
| Early BM relapse (<18 mo) | 7 (28) |
| Intermediate BM relapse (18-36 mo) | 2 (8) |
| Late BM relapse (> 36 mo) | 4 (16) |
| ≥2 BM relapse | 1 (4) |
| Refractory | 2 (8) |
| Poor response, with salvage chemotherapy | 4 (16) |
| BM blasts, median (range), % | 4 (1-98) |
| Distribution | |
| <5% (pretreatment MRD cohort) | 15 (60%) |
| ≥5% (pretreatment morphologic cohort) | 10 (40%) |
| Dose intensity of conditioning chemotherapy, n (%) | |
| HD-Cy | 17 (68) |
| LD-Cy | 8 (32) |
| Characteristic . | Patients (n = 25) . |
|---|---|
| Age, median (range), y | 13.5 (1-22.5) |
| Risk category, n (%) | |
| Relapse following allo-HSCT | 5 (20) |
| Early BM relapse (<18 mo) | 7 (28) |
| Intermediate BM relapse (18-36 mo) | 2 (8) |
| Late BM relapse (> 36 mo) | 4 (16) |
| ≥2 BM relapse | 1 (4) |
| Refractory | 2 (8) |
| Poor response, with salvage chemotherapy | 4 (16) |
| BM blasts, median (range), % | 4 (1-98) |
| Distribution | |
| <5% (pretreatment MRD cohort) | 15 (60%) |
| ≥5% (pretreatment morphologic cohort) | 10 (40%) |
| Dose intensity of conditioning chemotherapy, n (%) | |
| HD-Cy | 17 (68) |
| LD-Cy | 8 (32) |
Characteristics of patients who underwent treatment with CD19-specific CAR T cells.